Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012
Published Date:February 22, 2013
Source:MMWR. Morbidity and mortality weekly report. 2013; 62(07):131-5
Corporate Authors:National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Diseases.
Keywords:Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & Dosage
Diphtheria-Tetanus-acellular Pertussis Vaccines/adverse Effects
Pregnancy Trimester, Third
Whooping Cough/prevention & Control
Series:MMWR. Morbidity and mortality weekly report
Description:In October 2011, in an effort to reduce the burden of pertussis in infants, the Advisory Committee on Immunization Practices (ACIP) recommended that unvaccinated pregnant women receive a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccination of women with Tdap during pregnancy is expected to provide some protection to infants from pertussis until they are old enough to be vaccinated themselves. Tdap given to pregnant women will stimulate the development of maternal antipertussis antibodies, which will pass through the placenta, likely providing the newborn with protection against pertussis in early life, and will protect the mother from pertussis around the time of delivery, making her less likely to become infected and transmit pertussis to her infant. The 2011 Tdap recommendation did not call for vaccinating pregnant women previously vaccinated with Tdap. On October 24, 2012, ACIP voted to recommend use of Tdap during every pregnancy. This report summarizes data considered and conclusions made by ACIP and provides guidance for implementing its recommendations. These updated recommendations on use of Tdap in pregnant women aim to optimize strategies for preventing pertussis morbidity and mortality in infants.
Supporting Files:No Additional Files
You May Also Like: